One drop of blood is all it takes
to test for any biomarker at home

DEMOCRATIZING

CLINICAL DATA

Investors SARS-CoV-2

INVESTORS

About

The company has a product for blood biomarker testing. Customers demand this type of product and several contacts have already been made with vital institutions in Denmark. Sales for professional use are commenced in 2020.

Read more

Investors

Here you will find the share information for Qlife Holding AB. Our press releases and financial quarterly reports, our annual reports, calendar and information about our corporate governance work. Qlife Holding AB aims for a fast and transparent accounting to shareholders and the financial market.

The company is listed on Nasdaq, First North Growth Market, Stockholm as from March 2, 2020

Continue

Egoo.health

The Egoo product is a platform for accurate bio-marker testing. At a low cost and with equipment easy to use, it measures and analyses the patient’s blood. The patient can do the testing at home themselves. Read more on our product page.

Egoo.health

Contact

If you have any questions about us or our ongoing IPO feel free to send us a message.

 

 

You agree by using this feature that your information is handled in accordance with applicable GDPR legislation.
2 + 18 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Film - EGOO HEALTH EXPLAINED

In less than four minutes, CEO Thomas Warthoe explains what Egoo Health is all about, how it works and why it makes a difference for ordinary people, medical staff and health institutions. 

Read more about us

NEWS/PRESS

2020-03-31
Qlife to expand the Egoo.Health platform with COVID-19 test through licence deal

Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.

2020-03-13
Corona virus, COVID-19, has limited impact on Qlife Holding AB

Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.

2020-03-02
Qlife commences trading on Nasdaq First North Growth Market

Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm.

2020-02-28
Qlife has been approved for listing on the Nasdaq First North Growth Market with first day of trading on March 2[nd,] 2020

The short name for the Company’s shares on Nasdaq First North is QLIFE. The short name for the TO1 series warrants is QLIFE TO1.

2020-01-29
Qlife announces CE-mark for professional use for its first biomarker capsule on the Egoo Home System.

The Egoo Home System is an integrated platform consisting of a small device, disposable capsules, each a test for a specific biomarker, and a digital infrastructure that can share data with patient

2019-11-28
New presentation from Stora Aktiedagen Stockholm on 25 Nov

CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Stockholm on 25 November.

2019-11-06
Presentation of Qlife on Stora Aktiedagen (Shareholder’s Day)

CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November.

2019-11-06
Top Danish politicians were excited when testing their own biomarkers with Egoo

The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier.

2019-10-31
Qlife is showcased by the Danish Minister of Health and the Minister for Industry

Qlife is showcased by the Danish Minister of Health and the Minister for Industry, Business and Financial Affairs for the launch of new public program for innovative purchasing of medical equipment